Real World Study of End-stage Liver Disease in China
1 other identifier
observational
10,000
1 country
1
Brief Summary
The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis often accompanied by a series of complications. Therefore, it is necessary to standardize the diagnosis and treatment of liver cirrhosis and its complications. End-stage liver disease mainly refers to the late stage of liver disease caused by various chronic liver damage. Its main feature is that liver function can not meet the physiological needs of human body. This study is a single-center, prospective and observational real-world study aimed at investigating and analyzing the current diagnosis and treatment of liver cirrhosis and end-stage liver disease in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 14, 2019
CompletedFirst Posted
Study publicly available on registry
July 30, 2019
CompletedStudy Start
First participant enrolled
September 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2029
ExpectedJuly 30, 2019
July 1, 2019
1 year
July 14, 2019
July 29, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Patient died during follow-up
Death occurred during 3 year
3 years
Secondary Outcomes (1)
Major events occurred during follow-up
3 years
Interventions
No intervation
Eligibility Criteria
The population who were diagnosed of acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure or hepatocellular carcinoma (stage III-IV)
You may qualify if:
- Informed consent of patients.
- Diagnosis of any of the following diseases: acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure and hepatocellular carcinoma (stage III-IV)
You may not qualify if:
- HIV antibody positive and AIDS patients
- Serious psychiatric history, especially depression. Severe mental illness is defined as major depression or psychosis, suicide attempts, hospitalization due to mental illness or a period of disability due to mental illness.
- Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.
- Patients with other malignant tumors (excluding those cured).
- Pregnant, lactating women or women of childbearing age who are ready to conceive.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Huashan Hospitallead
Study Sites (1)
HuaShan Hospital
Shanghai, Shanghai Municipality, 200040, China
Related Publications (1)
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1151-1210. doi: 10.1016/S0140-6736(17)32152-9.
PMID: 28919116BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of dpartment of infectious disease
Study Record Dates
First Submitted
July 14, 2019
First Posted
July 30, 2019
Study Start
September 1, 2019
Primary Completion
September 1, 2020
Study Completion (Estimated)
September 1, 2029
Last Updated
July 30, 2019
Record last verified: 2019-07